EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia

Xinyue Zhou iD, Lixia Zhang, Sajesan Aryal, Virginia Veasey iD, Amanda Tajik iD, Cecilia Restelli iD, Steven Moreira iD, Pengcheng Zhang, Yanfeng Zhang iD, Kristin J Hope, Yang Zhou iD, Changde Cheng iD und 2 weitere

Blood · 07.11.2024 · 144 (19) · 2018-2032

DOI: 10.1182/blood.2023023644 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 07.11.2024. Verfasst von Xinyue Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins, Leukemia, Myeloid, Acute, Epigenesis, Genetic. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Menin inhibitors that disrupt the menin-MLL interaction hold promise for treating specific acute myeloid leukemia (AML) subtypes, including those with KMT2A rearrangements (KMT2A-r), yet resistance remains a challenge. Here, through systematic chromatin-focused CRISPR screens, along with genetic, epigenetic, and pharmacologic studies in a variety of human and mouse KMT2A-r AML models, we uncovered a potential resistance mechanism independent of canonical menin-MLL targets. We show that a group of noncanonical menin targets, which are bivalently cooccupied by active menin and repressive H2AK119ub marks, are typically downregulated after menin inhibition. Loss of polycomb repressive complex 1.1 (PRC1.1) subunits, such as polycomb group ring finger 1 (PCGF1) or BCL6 corepressor (BCOR), leads to menin inhibitor resistance by epigenetic reactivation of these noncanonical targets, including MYC. Genetic and pharmacological inhibition of MYC can resensitize PRC1.1-deficient leukemia cells to menin inhibition. Moreover, we demonstrate that leukemia cells with the loss of PRC1.1 subunits exhibit reduced monocytic gene signatures and are susceptible to BCL2 inhibition, and that combinational treatment with venetoclax overcomes the resistance to menin inhibition in PRC1.1-deficient leukemia cells. These findings highlight the important roles of PRC1.1 and its regulated noncanonical menin targets in modulating the menin inhibitor response and provide potential strategies to treat leukemia with compromised PRC1.1 function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene ProteinsLeukemia, Myeloid, AcuteEpigenesis, GeneticHumansMiceAnimalsGene Expression Regulation, LeukemicDrug Resistance, NeoplasmCell Line, TumorPolycomb Repressive Complex 1SulfonamidesMyeloid-Lymphoid Leukemia ProteinBridged Bicyclo Compounds, HeterocyclicHistone-Lysine N-MethyltransferaseRepressor ProteinsAntineoplastic Agents

Substanzen

Proto-Oncogene ProteinsMEN1 protein, humanvenetoclaxPolycomb Repressive Complex 1SulfonamidesMyeloid-Lymphoid Leukemia ProteinMen1 protein, mouseBCOR protein, humanBridged Bicyclo Compounds, HeterocyclicHistone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL.
  • O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL.
  • Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Department of Genetics, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL.

ORCID-Profile: Xinyue Zhou, Virginia Veasey, Amanda Tajik, Cecilia Restelli, Steven Moreira, Yanfeng Zhang, Yang Zhou, Changde Cheng, Rui Lu

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Zhou, X., Zhang, L., Aryal, S., Veasey, V., Tajik, A., Restelli, C., Moreira, S., Zhang, P., Zhang, Y., Hope, K. J., Zhou, Y., Cheng, C., Bhatia, R., & Lu, R. (2024). Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia. Blood, 144(19), 2018-2032. https://doi.org/10.1182/blood.2023023644

Vancouver

Zhou X, Zhang L, Aryal S, Veasey V, Tajik A, Restelli C, et al. Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia. Blood. 2024;144(19):2018-2032. doi:10.1182/blood.2023023644

BibTeX
@article{Zhou2024,
  author = {Zhou, Xinyue and Zhang, Lixia and Aryal, Sajesan and Veasey, Virginia and Tajik, Amanda and Restelli, Cecilia and Moreira, Steven and Zhang, Pengcheng and Zhang, Yanfeng and Hope, Kristin J and Zhou, Yang and Cheng, Changde and Bhatia, Ravi and Lu, Rui},
  title = {Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia},
  journal = {Blood},
  year = {2024},
  volume = {144},
  number = {19},
  pages = {2018--2032},
  doi = {10.1182/blood.2023023644}
}
Kostenlos starten →